Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Indivior Pharmaceuticals (INDV) EBT (2024 - 2025)

Indivior Pharmaceuticals (INDV) has 2 years of EBT data on record, last reported at $780.0 million in Q4 2025.

  • For Q4 2025, EBT rose 1952.63% year-over-year to $780.0 million; the TTM value through Dec 2025 reached $938.0 million, up 4590.0%, while the annual FY2025 figure was $239.0 million, 1095.0% up from the prior year.
  • EBT reached $780.0 million in Q4 2025 per INDV's latest filing, up from $37.0 million in the prior quarter.
  • Across five years, EBT topped out at $780.0 million in Q4 2025 and bottomed at -$121.0 million in Q2 2024.